MAP2K7 and Miyoshi myopathy: However, RAS pathway-driven cancers, including MM, are particularly aggressive and are refractory to current therapeutic interventions (mainly RAF and MEK inhibitors), typically due to narrow therapeutic windows, paradoxical pathway activation, feedback induction of phosphatidylinositol-3 kinase/Akt signaling, and/or drug resistance, demonstrating an unmet medical need [10].